testosterone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
androgens/anabolic steroids 2607 58-22-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • testosterone
  • 17beta-Testosterone
A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.
  • Molecular weight: 288.43
  • Formula: C19H28O2
  • CLOGP: 3.41
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 37.30
  • ALOGS: -3.94
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.12 g O
18 mg P
0.12 g R
60 mg SL
50 mg TD
3 mg TD

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.97 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 4 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.35 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 24.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.17 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 13, 1972 FDA ACTIENT PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood testosterone increased 262.82 22.43 36 2711 117 46683198
Accidental exposure to product 243.18 22.43 77 2670 21004 46662311
Expulsion of medication 145.05 22.43 17 2730 4 46683311
Virilism 135.89 22.43 17 2730 19 46683296
Precocious puberty 119.70 22.43 19 2728 200 46683115
Enlarged clitoris 118.53 22.43 18 2729 138 46683177
Hair growth abnormal 113.40 22.43 27 2720 2531 46680784
Accidental exposure to product by child 61.09 22.43 14 2733 1109 46682206
Off label use 59.99 22.43 91 2656 379750 46303565
Renal infarct 44.38 22.43 11 2736 1216 46682099
Metaplasia 42.92 22.43 9 2738 471 46682844
Skin laceration 42.31 22.43 21 2726 18481 46664834
Hirsutism 41.49 22.43 10 2737 984 46682331
Atherosclerotic plaque rupture 41.36 22.43 5 2742 3 46683312
Infertility 40.31 22.43 9 2738 633 46682682
Borderline serous tumour of ovary 37.89 22.43 5 2742 11 46683304
Blood testosterone decreased 31.12 22.43 5 2742 57 46683258
Vaginal disorder 29.17 22.43 7 2740 676 46682639
Chorioretinopathy 28.60 22.43 7 2740 734 46682581
Acne 27.03 22.43 16 2731 19903 46663412
Apocrine breast carcinoma 26.22 22.43 3 2744 0 46683315
Breast cancer 24.99 22.43 21 2726 45497 46637818
Focal segmental glomerulosclerosis 24.09 22.43 7 2740 1414 46681901
Adnexal torsion 24.08 22.43 5 2742 249 46683066
Libido increased 23.35 22.43 6 2741 766 46682549
Exposure via skin contact 23.30 22.43 4 2743 70 46683245
Osteonecrosis 23.27 22.43 16 2731 25728 46657587

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood testosterone decreased 1397.41 11.56 394 28569 4002 29919513
Blood testosterone increased 465.60 11.56 122 28841 910 29922605
Polycythaemia 269.37 11.56 90 28873 1662 29921853
Application site rash 239.29 11.56 69 28894 760 29922755
Product administered at inappropriate site 235.61 11.56 80 28883 1555 29921960
Deep vein thrombosis 196.09 11.56 266 28697 60235 29863280
Expulsion of medication 177.89 11.56 32 28931 15 29923500
Product deposit 177.57 11.56 43 28920 222 29923293
Blood testosterone abnormal 173.57 11.56 42 28921 216 29923299
Incorrect dose administered 159.19 11.56 174 28789 31512 29892003
Haematocrit increased 144.05 11.56 56 28907 1620 29921895
Application site pain 133.90 11.56 53 28910 1610 29921905
Pulmonary embolism 126.44 11.56 251 28712 77884 29845631
Precocious puberty 117.81 11.56 26 28937 81 29923434
Implant site pain 117.11 11.56 27 28936 108 29923407
Prescribed overdose 114.41 11.56 82 28881 8479 29915036
Application site erythema 114.10 11.56 52 28911 2251 29921264
Testicular atrophy 96.71 11.56 31 28932 499 29923016
Infertility male 86.88 11.56 23 28940 179 29923336
Toxicity to various agents 85.98 11.56 32 28931 177151 29746364
Application site pruritus 83.90 11.56 36 28927 1347 29922168
Insulin-like growth factor increased 83.19 11.56 33 28930 1008 29922507
Libido decreased 83.17 11.56 53 28910 4513 29919002
Product quality issue 80.48 11.56 95 28868 18679 29904836
Death 75.29 11.56 145 28818 357138 29566377
Product odour abnormal 73.46 11.56 26 28937 574 29922941
Application site reaction 73.01 11.56 24 28939 420 29923095
Pituitary tumour benign 68.46 11.56 27 28936 812 29922703
Gynaecomastia 64.47 11.56 58 28905 8293 29915222
Craniopharyngioma 64.32 11.56 20 28943 290 29923225
Blood testosterone free decreased 63.72 11.56 15 28948 67 29923448
Hypogonadism 60.86 11.56 29 28934 1390 29922125
Erectile dysfunction 60.67 11.56 81 28882 18021 29905494
Prostatic specific antigen increased 60.37 11.56 66 28897 11938 29911577
Febrile neutropenia 59.38 11.56 15 28948 106678 29816837
Application site exfoliation 57.93 11.56 15 28948 106 29923409
Oestradiol increased 55.75 11.56 12 28951 32 29923483
Application site irritation 54.76 11.56 22 28941 695 29922820
Neutropenia 54.72 11.56 28 28935 128512 29795003
Azoospermia 54.39 11.56 19 28944 403 29923112
Hair growth abnormal 53.51 11.56 21 28942 623 29922892
Application site dryness 52.66 11.56 12 28951 45 29923470
Secondary hypogonadism 52.22 11.56 17 28946 288 29923227
Device expulsion 51.34 11.56 13 28950 83 29923432
Performance enhancing product use 49.70 11.56 13 28950 96 29923419
Osteonecrosis 49.23 11.56 69 28894 16066 29907449
Haemoglobin increased 48.71 11.56 32 28931 2870 29920645
Completed suicide 48.14 11.56 18 28945 99474 29824041
Application site vesicles 48.09 11.56 19 28944 574 29922941
Feeling abnormal 48.01 11.56 142 28821 56614 29866901
Poor quality product administered 47.89 11.56 26 28937 1643 29921872
Thrombocytopenia 47.21 11.56 38 28925 137006 29786509
General physical health deterioration 46.84 11.56 19 28944 99925 29823590
Muscle mass 46.31 11.56 15 28948 250 29923265
Clear cell renal cell carcinoma 46.05 11.56 21 28942 910 29922605
Red blood cell count increased 45.90 11.56 24 28939 1405 29922110
Focal segmental glomerulosclerosis 45.69 11.56 26 28937 1801 29921714
Implant site bruising 45.00 11.56 8 28955 3 29923512
Drug ineffective 44.85 11.56 514 28449 339873 29583642
Hyperoestrogenism 43.66 11.56 8 28955 5 29923510
Implant site infection 42.96 11.56 20 28943 909 29922606
Pyrexia 42.92 11.56 144 28819 294345 29629170
Sleep apnoea syndrome 41.25 11.56 65 28898 16792 29906723
Wrong technique in product usage process 40.90 11.56 92 28871 31063 29892452
Acute myocardial infarction 40.60 11.56 128 28835 52811 29870704
Prostate cancer 39.91 11.56 78 28885 23879 29899636
Cerebrovascular accident 38.99 11.56 172 28791 83305 29840210
Insulin-like growth factor decreased 38.16 11.56 13 28950 255 29923260
Infertility 37.97 11.56 12 28951 184 29923331
Thrombosis 36.98 11.56 107 28856 42124 29881391
Drug abuse 36.74 11.56 167 28796 81905 29841610
Application site discolouration 36.29 11.56 12 28951 214 29923301
Acne 35.95 11.56 45 28918 9391 29914124
Anaemia 35.06 11.56 95 28868 207897 29715618
Acute kidney injury 34.57 11.56 142 28821 273700 29649815
Drug interaction 34.51 11.56 90 28873 199478 29724037
Application site urticaria 33.89 11.56 9 28954 71 29923444
Mesenteric vein thrombosis 32.92 11.56 14 28949 512 29923003
Blood oestrogen increased 32.92 11.56 8 28955 42 29923473
Product container issue 32.69 11.56 16 28947 814 29922701
Myocardial infarction 32.31 11.56 220 28743 125405 29798110
Drug-disease interaction 31.07 11.56 11 28952 243 29923272
Blood testosterone free increased 29.78 11.56 6 28957 10 29923505
Virilism 29.71 11.56 5 28958 0 29923515
Product administration error 29.22 11.56 51 28912 14326 29909189
Interstitial lung disease 28.92 11.56 11 28952 60186 29863329
Product physical consistency issue 28.83 11.56 11 28952 302 29923213
Pancytopenia 28.74 11.56 24 28939 85028 29838487
Sepsis 28.48 11.56 62 28901 146333 29777182
Headache 28.40 11.56 285 28678 182021 29741494
Product dose omission issue 28.20 11.56 168 28795 91463 29832052
Lymphoproliferative disorder 28.14 11.56 21 28942 2309 29921206
Implant site haemorrhage 27.91 11.56 8 28955 86 29923429
Breast cancer 27.76 11.56 11 28952 335 29923180
Implant site swelling 27.19 11.56 8 28955 95 29923420
Product physical issue 27.16 11.56 20 28943 2154 29921361
Septic shock 26.82 11.56 14 28949 63593 29859922
Pneumonia 26.54 11.56 202 28761 334104 29589411
Malignant neoplasm progression 26.19 11.56 19 28944 72268 29851247
Depression 26.05 11.56 163 28800 90274 29833241
Coronary artery disease 25.95 11.56 106 28857 49606 29873909
Myocardial fibrosis 25.73 11.56 13 28950 708 29922807
Left ventricular hypertrophy 25.63 11.56 31 28932 6247 29917268
Hyperhidrosis 25.31 11.56 130 28833 66960 29856555
Stubbornness 25.10 11.56 6 28957 29 29923486
Pituitary tumour recurrent 25.06 11.56 7 28956 68 29923447
Muscle hypertrophy 24.93 11.56 6 28957 30 29923485
Anger 24.64 11.56 41 28922 11079 29912436
Product storage error 23.59 11.56 30 28933 6361 29917154
Application site dermatitis 23.34 11.56 6 28957 41 29923474
Fatigue 23.30 11.56 437 28526 320236 29603279
Hypogonadism male 23.19 11.56 9 28954 259 29923256
Renal failure 23.16 11.56 57 28906 128909 29794606
Acne fulminans 23.06 11.56 8 28955 166 29923349
Neoplasm recurrence 22.93 11.56 17 28946 1850 29921665
Insulin resistance 22.63 11.56 11 28952 551 29922964
Cholelithiasis 22.49 11.56 56 28907 20169 29903346
Blood follicle stimulating hormone decreased 22.30 11.56 6 28957 50 29923465
Blood luteinising hormone decreased 21.70 11.56 7 28956 115 29923400
Hypotension 21.69 11.56 110 28853 200455 29723060
Loss of libido 21.58 11.56 17 28946 2025 29921490
Melaena 21.34 11.56 3 28960 32434 29891081
Stomatitis 21.19 11.56 5 28958 37274 29886241
Injection site pain 21.16 11.56 71 28892 30239 29893276
Treatment failure 21.04 11.56 4 28959 34675 29888840
Intentional overdose 20.91 11.56 7 28956 41474 29882041
Hypercoagulation 20.88 11.56 13 28950 1062 29922453
Pituitary tumour 20.80 11.56 10 28953 489 29923026
Hormone level abnormal 20.79 11.56 9 28954 344 29923171
Decreased appetite 20.62 11.56 75 28888 149835 29773680
Renal infarct 20.30 11.56 13 28950 1116 29922399
Implant site erythema 20.18 11.56 6 28957 74 29923441
Multiple organ dysfunction syndrome 20.14 11.56 19 28944 63468 29860047
Application site paraesthesia 20.11 11.56 4 28959 6 29923509
Glucose tolerance decreased 19.97 11.56 6 28957 77 29923438
Therapeutic response unexpected 19.96 11.56 33 28930 8870 29914645
Breast tenderness 19.89 11.56 11 28952 721 29922794
Platelet count decreased 19.77 11.56 46 28917 106083 29817432
Chorioretinopathy 19.60 11.56 14 28949 1438 29922077
Cardio-respiratory arrest 19.56 11.56 16 28947 57290 29866225
Oligospermia 19.55 11.56 6 28957 83 29923432
Product complaint 19.47 11.56 26 28937 5780 29917735
Accidental exposure to product 19.41 11.56 35 28928 10080 29913435
Skin irritation 19.27 11.56 22 28941 4170 29919345
Cardiac death 18.83 11.56 12 28951 1021 29922494
Leukopenia 18.78 11.56 16 28947 56143 29867372
Implant site mass 18.77 11.56 4 28959 10 29923505
Factor V Leiden mutation 18.49 11.56 4 28959 11 29923504
Transient ischaemic attack 18.46 11.56 60 28903 25140 29898375
Expired product administered 18.44 11.56 18 28945 2851 29920664
Cardiac failure 18.21 11.56 33 28930 83385 29840130
Confusional state 18.18 11.56 68 28895 134766 29788749
Blood growth hormone increased 18.12 11.56 7 28956 199 29923316
Application site inflammation 17.94 11.56 6 28957 111 29923404
Acromegaly 17.86 11.56 5 28958 49 29923466
Angiofibroma 17.83 11.56 3 28960 0 29923515
C-reactive protein increased 17.70 11.56 10 28953 43463 29880052
Growth hormone-producing pituitary tumour 17.55 11.56 4 28959 15 29923500
Prostatomegaly 17.49 11.56 22 28941 4614 29918901
Needle issue 17.43 11.56 20 28943 3812 29919703
Spinal cord abscess 17.40 11.56 7 28956 222 29923293
Portal vein thrombosis 17.33 11.56 19 28944 3445 29920070
Thyroxine decreased 17.32 11.56 6 28957 124 29923391
Growth accelerated 17.15 11.56 4 28959 17 29923498
Acne conglobata 17.15 11.56 4 28959 17 29923498
Amnesia 17.00 11.56 57 28906 24264 29899251
Obesity 16.93 11.56 30 28933 8525 29914990
Bone marrow failure 16.92 11.56 4 28959 29781 29893734
Application site burn 16.67 11.56 7 28956 248 29923267
Gastrointestinal haemorrhage 16.49 11.56 35 28928 83411 29840104
Disease progression 16.21 11.56 33 28930 79841 29843674
Cerebral venous thrombosis 16.16 11.56 9 28954 598 29922917
Underdose 16.09 11.56 36 28927 12105 29911410
Bradycardia 16.09 11.56 24 28939 65502 29858013
Circumstance or information capable of leading to medication error 16.09 11.56 13 28950 1606 29921909
Aortic aneurysm 16.06 11.56 25 28938 6388 29917127
Anorgasmia 16.05 11.56 9 28954 606 29922909
Liquid product physical issue 15.92 11.56 7 28956 278 29923237
Implant site cellulitis 15.87 11.56 4 28959 25 29923490
Dermal absorption impaired 15.75 11.56 3 28960 3 29923512
Implant site necrosis 15.75 11.56 3 28960 3 29923512
Mucosal inflammation 15.62 11.56 5 28958 30489 29893026
Stress 15.56 11.56 49 28914 20186 29903329
Penis disorder 15.48 11.56 11 28952 1121 29922394
Hyperkalaemia 15.42 11.56 25 28938 65985 29857530
Sperm concentration zero 15.29 11.56 3 28960 4 29923511
Testis discomfort 15.29 11.56 3 28960 4 29923511
Testicular pain 15.27 11.56 16 28947 2756 29920759
Blood thyroid stimulating hormone decreased 14.72 11.56 13 28950 1814 29921701
Retinal vein occlusion 14.40 11.56 12 28951 1547 29921968
Irritability 14.36 11.56 52 28911 22998 29900517
Intentional product misuse 14.36 11.56 69 28894 34598 29888917
Hepatic adenoma 14.31 11.56 4 28959 39 29923476
Congestive cardiomyopathy 14.11 11.56 24 28939 6603 29916912
Thrombophlebitis superficial 13.98 11.56 15 28948 2654 29920861
Ophthalmic vein thrombosis 13.96 11.56 4 28959 43 29923472
Orchidectomy 13.63 11.56 4 28959 47 29923468
Empty sella syndrome 13.48 11.56 4 28959 49 29923466
Drug withdrawal syndrome 13.47 11.56 46 28917 19763 29903752
Nipple pain 13.31 11.56 8 28955 614 29922901
Dehydration 13.19 11.56 68 28895 123471 29800044
Neutrophil count decreased 13.12 11.56 13 28950 42441 29881074
Eye colour change 13.03 11.56 6 28957 266 29923249
Skin odour abnormal 12.92 11.56 9 28954 888 29922627
Sperm concentration decreased 12.91 11.56 5 28958 143 29923372
Mood swings 12.90 11.56 25 28938 7601 29915914
Thyrotoxic periodic paralysis 12.68 11.56 4 28959 61 29923454
Gastric hypomotility 12.56 11.56 4 28959 63 29923452
Device extrusion 12.47 11.56 3 28960 15 29923500
Drug reaction with eosinophilia and systemic symptoms 12.41 11.56 6 28957 28482 29895033
Hyperglycaemic hyperosmolar nonketotic syndrome 12.26 11.56 9 28954 965 29922550
Pollakiuria 12.15 11.56 40 28923 16866 29906649
Astrocytoma 11.96 11.56 5 28958 175 29923340
Dyspnoea 11.95 11.56 239 28724 333056 29590459
Cardiomyopathy 11.95 11.56 37 28926 15106 29908409
Autoimmune thyroiditis 11.89 11.56 9 28954 1011 29922504
Diarrhoea 11.85 11.56 240 28723 333863 29589652
Cardiac arrest 11.76 11.56 48 28915 92802 29830713
Penile size reduced 11.73 11.56 5 28958 184 29923331
Carotid artery occlusion 11.72 11.56 12 28951 2013 29921502
Gamma-glutamyltransferase increased 11.59 11.56 7 28956 29343 29894172
Oxygen saturation decreased 11.57 11.56 15 28948 43425 29880090

Pharmacologic Action:

SourceCodeDescription
ATC G03BA03 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
ANDROGENS
3-oxoandrosten (4) derivatives
ATC G03EA02 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION
Androgens and estrogens
FDA CS M0001109 Androstanes
FDA MoA N0000000146 Androgen Receptor Agonists
FDA EPC N0000175824 Androgen
MeSH PA D000728 Androgens
MeSH PA D006728 Hormones
CHEBI has role CHEBI:50113 androgens
CHEBI has role CHEBI:75771 mus musculus metabolite
CHEBI has role CHEBI:77746 h. sapiens metabolites
CHEBI has role CHEBI:83056 daphnia magna metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypogonadotropic hypogonadism indication 33927004
Deficiency of testosterone biosynthesis indication 38825009
Inhibition of lactation procedure indication 43141007
Male hypogonadism indication 48723006
Hypopituitarism indication 74728003 DOID:9406
Menopausal flushing indication 198436008
Undescended testicle indication 204878001 DOID:11383
Bilateral orchidectomy indication 386634006
Delayed puberty indication 400003000
Klinefelter's syndrome, XXY indication 405769009
Hormone receptor positive malignant neoplasm of breast indication 417181009
Primary Hypogonadism due to Bilateral Torsion indication
Primary Hypogonadism due to Orchitis indication
LHRH Deficiency indication
Chemotherapy-Induced Hypogonadism indication
Bilateral Anorchia indication
Noonan's syndrome off-label use 205824006 DOID:3490
Hyperlipoproteinemia contraindication 3744001 DOID:1168
Gynecomastia contraindication 4754008 DOID:12698
Hypocalcemia contraindication 5291005
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Chloasma contraindication 36209000
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Body fluid retention contraindication 43498006
Thrombosis of retinal vein contraindication 46085004
Humoral hypercalcemia of malignancy contraindication 47709007
Chronic heart failure contraindication 48447003
Dementia contraindication 52448006
Hepatic porphyria contraindication 55056006 DOID:3133
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Heart disease contraindication 56265001 DOID:114
Thrombophlebitis contraindication 64156001 DOID:3875
Intermenstrual bleeding - irregular contraindication 64996003
Hypercalcemia contraindication 66931009 DOID:12678
Arteriosclerotic vascular disease contraindication 72092001
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050847
Heart failure contraindication 84114007 DOID:6000
Epilepsy contraindication 84757009 DOID:1826
Breast lump contraindication 89164003
Kidney disease contraindication 90708001 DOID:557
Uterine leiomyoma contraindication 95315005 DOID:13223
Magnetic resonance imaging contraindication 113091000
Neoplasm of liver contraindication 126851005 DOID:3571
Neoplasm of prostate contraindication 126906006 DOID:10283
Deep venous thrombosis contraindication 128053003
Endometriosis contraindication 129103003
Mammography abnormal contraindication 168750009
Asthma contraindication 195967001 DOID:2841
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Endometrial carcinoma contraindication 254878006 DOID:2871
Benign prostatic hyperplasia contraindication 266569009
Edema contraindication 267038008
Chorea contraindication 271700006
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Functional visual loss contraindication 313165001
Malignant tumor of ovary contraindication 363443007 DOID:2394
Thromboembolic disorder contraindication 371039008
Cardiovascular event risk contraindication 395112001
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Family history of malignant neoplasm of breast contraindication 429740004
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002
Breast Carcinoma in Males contraindication

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Androgen receptor Nuclear hormone receptor AGONIST EC50 9.20 WOMBAT-PK CHEMBL
Glucocorticoid receptor Nuclear hormone receptor Ki 5.84 DRUG MATRIX
Aromatase Enzyme Ki 6.22 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.92 CHEMBL
Sex hormone-binding globulin Secreted Kd 9.20 CHEMBL
Lanosterol 14-alpha demethylase Enzyme IC50 4.30 CHEMBL
Corticosteroid-binding globulin Secreted Ki 6.72 CHEMBL
Progesterone receptor Transcription factor Ki 6.60 DRUG MATRIX
Steroid 5-alpha-reductase Enzyme IC50 5.72 CHEMBL
Androgen receptor Transcription factor Ki 8.85 CHEMBL
Constitutive androstane receptor Unclassified IC50 4.52 CHEMBL
C-8 sterol isomerase Enzyme Ki 5.11 CHEMBL

External reference:

IDSource
4017484 VUID
N0000145872 NUI
D00075 KEGG_DRUG
4017484 VANDF
C0039601 UMLSCUI
CHEBI:17347 CHEBI
TES PDB_CHEM_ID
CHEMBL386630 ChEMBL_ID
CHEMBL1201101 ChEMBL_ID
D013739 MESH_DESCRIPTOR_UI
1900 INN_ID
DB00624 DRUGBANK_ID
3XMK78S47O UNII
6013 PUBCHEM_CID
2858 IUPHAR_LIGAND_ID
10379 RXNORM
2966 MMSL
5552 MMSL
d00558 MMSL
001245 NDDF
109033004 SNOMEDCT_US
43688007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Androderm HUMAN PRESCRIPTION DRUG LABEL 1 0023-5990 PATCH 2 mg TRANSDERMAL NDA 34 sections
Androderm HUMAN PRESCRIPTION DRUG LABEL 1 0023-5992 PATCH 4 mg TRANSDERMAL NDA 34 sections
Androgel HUMAN PRESCRIPTION DRUG LABEL 1 0051-8425 GEL 10 mg TRANSDERMAL NDA 30 sections
Androgel HUMAN PRESCRIPTION DRUG LABEL 1 0051-8450 GEL 10 mg TRANSDERMAL NDA 30 sections
Androgel HUMAN PRESCRIPTION DRUG LABEL 1 0051-8462 GEL 16.20 mg TRANSDERMAL NDA 29 sections
Androgel HUMAN PRESCRIPTION DRUG LABEL 1 0051-8488 GEL 10 mg TRANSDERMAL NDA 30 sections
Vogelxo HUMAN PRESCRIPTION DRUG LABEL 1 0245-0871 GEL 50 mg TOPICAL NDA 37 sections
Vogelxo HUMAN PRESCRIPTION DRUG LABEL 1 0245-0872 GEL, METERED 12.50 mg TOPICAL NDA 37 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0254-1012 GEL 50 mg TRANSDERMAL NDA AUTHORIZED GENERIC 33 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0591-2114 SOLUTION 30 mg TOPICAL ANDA 33 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0591-2363 GEL, METERED 10 mg TOPICAL ANDA 33 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0591-2921 GEL 10 mg TOPICAL ANDA 32 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0591-2924 GEL 16.20 mg TRANSDERMAL ANDA 32 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0591-2925 GEL 16.20 mg TRANSDERMAL ANDA 32 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0591-2926 GEL 16.20 mg TRANSDERMAL ANDA 32 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0591-3216 GEL 10 mg TOPICAL ANDA 32 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0591-3217 GEL 10 mg TOPICAL ANDA 32 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0591-3524 GEL 50 mg TRANSDERMAL ANDA 30 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0603-7831 GEL, METERED 10 mg TOPICAL NDA AUTHORIZED GENERIC 34 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0832-1120 GEL 50 mg TOPICAL NDA authorized generic 35 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0832-1121 GEL, METERED 12.50 mg TOPICAL NDA authorized generic 35 sections
Testim HUMAN PRESCRIPTION DRUG LABEL 1 16590-853 GEL 50 mg TOPICAL NDA 13 sections
testosterone HUMAN PRESCRIPTION DRUG LABEL 1 16714-967 GEL 20.25 mg TOPICAL ANDA 33 sections
testosterone HUMAN PRESCRIPTION DRUG LABEL 1 16714-968 GEL 20.25 mg TOPICAL ANDA 33 sections
testosterone HUMAN PRESCRIPTION DRUG LABEL 1 16714-969 GEL 40.50 mg TOPICAL ANDA 33 sections
Androgel HUMAN PRESCRIPTION DRUG LABEL 1 21695-112 GEL 10 mg TRANSDERMAL NDA 18 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 24979-078 GEL 16.20 mg TRANSDERMAL ANDA 29 sections
Natestonasal gel HUMAN PRESCRIPTION DRUG LABEL 1 42667-5511 GEL, METERED 5.50 mg NULLSAL NDA 33 sections
Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 43598-304 GEL, METERED 1.62 mg TRANSDERMAL ANDA 31 sections
Testopel HUMAN PRESCRIPTION DRUG LABEL 1 43773-1001 PELLET 75 mg SUBCUTANEOUS ANDA 12 sections